A model-based meta-analysis of the effect of latanoprost chronotherapy on the circadian intraocular pressure of patients with glaucoma or ocular hypertension.
Several reports have demonstrated that the efficacy of latanoprost is influenced by the time of dosing. This model-based meta-analysis validates previous findings that evening dosing is superior to morning dosing and predicts the optimal time for dosing, based on the quantitative assessment of baseline and latanoprost-treated 24-h circadian intraocular pressure (IOP) curves. The results confirm the importance of the time of dosing as a factor that influences the extent of reduction in IOP and underline the need to take this factor into consideration in the design of glaucoma trials and therapy.
Luu
K T
KT
Department of Pharmacokinetics, Dynamics, and Metabolism, Pfizer Global Research and Development, La Jolla, California, USA. kenneth.luu@pfizer.com
Raber
S R
SR
Nickens
D J
DJ
Vicini
P
P
D000959:Antihypertensive Agents / Q000008:administration & dosage* / Q000494:pharmacology; D002940:Circadian Rhythm; D004334:Drug Administration Schedule; D005902:Glaucoma, Open-Angle / Q000188:drug therapy / Q000503:physiopathology; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects*; D000077338:Latanoprost; D009798:Ocular Hypertension / Q000188:drug therapy / Q000503:physiopathology; D011461:Prostaglandins F, Synthetic / Q000008:administration & dosage* / Q000494:pharmacology
D000959:Antihypertensive Agents; D011461:Prostaglandins F, Synthetic; D000077338:Latanoprost